Eikon Therapeutics

Eikon Therapeutics is a biopharmaceutical startup aiming to revolutionize drug discovery through an innovative approach based on tracking and measuring the movement of individual proteins in live cells. Founded in 2019 and headquartered in the United States, the company has attracted significant investments, with the latest being a $106.00M Series C investment in June 2023.

Utilizing groundbreaking technology developed by its founders, including a Nobel Prize laureate in 2014, Eikon has engineered microscopes capable of real-time, molecular-resolution measurements of protein movement in living cells. This pioneering platform enables the direct measurement of chemical compounds' effects on protein behavior in a live cellular environment, leading to the sensitive identification of compound-protein interactions that were previously inaccessible through traditional assays.

Eikon's high-powered high-content data sets generated by its drug-screening technology offer an unprecedented opportunity to quantitatively explore novel biology in the living cell, providing valuable insights into disease mechanisms. The company's focus on interdisciplinary scientific exploration and data-driven hypotheses has attracted attention and investment, presenting an exciting opportunity for those interested in joining the team to contribute to this radical drug-discovery paradigm and the creation of novel medicines.

To learn more about open positions at Eikon Therapeutics, interested individuals can visit their website: https://eikontx.com/team#positions.